The history of phenotypic testing in thrombosis and hemostasis

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 7, 2008, Pages 585-592

  Tripodi, Armando ^a,b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b NONE   (Italy)

Author keywords

APTT; Coagulation tests; PT; Synthetic substrates; Thrombin generation

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; COUMARIN; FIBRINOGEN; HEPARIN; LUPUS ANTICOAGULANT; PROTHROMBIN; THROMBOPLASTIN; VITAMIN K GROUP;

BLOOD CLOTTING; BLOOD CLOTTING TIME; CHRONIC LIVER DISEASE; CLINICAL LABORATORY; COMPUTER ASSISTED DIAGNOSIS; DRUG MONITORING; FIBRIN FORMATION; HEMOPHILIA; HEMOSTASIS; HISTORY OF MEDICINE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LUPUS ERYTHEMATOSUS; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; PRIORITY JOURNAL; REVIEW; THROMBIN TIME; THROMBOELASTOGRAPHY; THROMBOSIS; THROMBOTEST; TREATMENT CONTRAINDICATION; VENOUS THROMBOEMBOLISM;

BLOOD COAGULATION TESTS; HEMOSTASIS; HEPARIN; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; THROMBELASTOGRAPHY; THROMBIN; THROMBOPLASTIN; THROMBOSIS;

EID: 58149083612     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0028-1104537     Document Type: Review

References (51)

1. Langdell RD, Wagner RH, Brinkhous KM. Effect of anti-hemophilic factor on one stage clotting tests: a presumptive test for hemophilia and a simple one-stage anti-hemophilic assay procedure. J Lab Clin Med 1953;41:637-647
2. Bell WN, Alton HG. A brain extract as a substitute for platelet suspension in the thromboplastin generation time. Nature 1954;174:880-881
3. Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961;36:212-219
4. Margolis J. The kaolin clotting time. A rapid one-stage method for diagnosis of coagulation defects. J Clin Pathol 1958;11:406-409
5. Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952;31:621-622
6. Bowie EJ, Thompson JH Jr, Pascuzzi CA, Owen CA Jr. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963;62:416-430
7. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324-327
8. Van der Velde EA, Poller L. The APTT monitoring of heparin-the ISTH/ICSH collaborative study. Thromb Haemost 1995;73:73-81
9. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993;90:1004-1008
10. Tripodi A, Chantarangkul V, Martinelli I, Bucciarelli P, Mannucci PM. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood 2004;104:3631-3634
11. Hron G, Eichinger S, Weltermann A, Quehenberger P, Halbmayer WM, Kyrle PA. Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time. J Thromb Haemost 2006;4:752-756
12. Lippi G, Favaloro EJ. Activated partial thromboplastin time: new tricks for an old dogma. Semin Thromb Hemost 2008;34:604-611
13. Quick AJ. The prothrombin in hemophilia and in obstructive jaundice. J Biol Chem 1935;109:73-74
14. Butt HR, Allen AV, Bollman JR. A preparation from spoiled sweet lover which prolong coagulation time of blood. Proc Staff Meet Mayo Clin 1941;16:388-395
15. Poller L. The effect of the use of different tissue extracts on one-stage prothrombin times. Acta Haematol 1964;32:292-298
16. Poller L. Standardization of anticoagulant treatment: the Manchester Regional Thromboplastin Scheme. Br Med J 1964;2:564-566
17. Owren PA. Thrombotest. A new method for controlling anticoagulant therapy. Lancet 1959;2:754-758
18. De Vries SI. Introduction to thrombotest at the Netherlands Thrombosis Service. In: Hemker HC, Loeliger EA, Veltkamp JJ, eds. Human Blood Coagulation. Leiden, The Netherlands: Leiden University Press; 1969:314-317
19. Biggs R, Denson KWE. Standardization of the one-stage prothrombin time for control of anticoagulant therapy. BMJ 1967;1:84-88
20. Bangham DR, Biggs R, Brozovic M, Denson KWE. Calibration of five different thromboplastins using fresh and freeze-dried plasma. Thromb Diath Haemorrh 1973;29:228-239
21. International Committee on Thrombosis and Haemostasis (ICTH) and International Committee for Standardization in Haematology (ICSH). Prothrombin time standardization: report of the export panel on anticoagulant control. Thromb Haemost 1979;42:1073-1114
22. Expert WHO Committee on Biological Standardization. Twenty-eighth report. Technical Report Series, No. 610. Geneva, Switzerland: WHO; 1977
23. Hermans J, van den Besselaar AM, Loeliger EA, van der Velde EA. A collaborative study of reference material for thromboplastins. Thromb Haemost 1983;50:712-717
24. Kirkwood TBL. Calibration of reference thromboplastins and standardization of the prothrombin time ratio. Thromb Haemost 1983;49:238-244
25. Expert WHO Committee on Biological Standardization. Thirty-third report. Technical Report Series, No. 687. Geneva, Switzerland: WHO; 1983
26. Van den Besselaar AMHP, Gralnick HR, Lewis SM, eds. Thromboplastin Calibration and Oral Anticoagulant Control. Boston, MA: Martinus Nijhoff Publishers; 1984
27. Thomson JM, Tomenson JA, Poller L. The calibration of second primary international reference preparation for thromboplastin (thromboplastin, human, plain, coded BCT/253). Thromb Haemost 1984;52:336-342
28. Tripodi A, Arbini A, Chantarangkul V, Mannucci PM. Recombinant tissue factor as substitute for conventional thromboplastin in the prothrombin time test. Thromb Haemost 1992;67:42-45
29. Tripodi A, Chantarangkul V, Braga M, et al. Results of a multicenter study assessing the status of standardization of a recombinant thromboplastin for the control of oral anticoagulant therapy. Thromb Haemost 1994;72:261-267
30. Tripodi A, Chantarangkul V, Negri B, Clerici M, Mannucci PM. International collaborative study for the calibration of a proposed reference preparation for thromboplastin, human recombinant, plain. On behalf of the Subcommittee on Control of Anticoagulation. Thromb Haemost 1998;79:439-443
31. van den Besselaar AMHP, Poller L, Tripodi A. World Health Organization (WHO) Guidelines for Thromboplastins and Plasma Used to Control Oral Anticoagulant Therapy. WHO Technical Report Series, No. 889. Geneva, Switzerland: WHO; 1999
32. Trotter JF, Brimhall B, Arjal R. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004;10:995-1000
33. Wiesner R, Edwards E, Freeman R, et al. United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor liver. Gastroenterology 2003;124:91-96
34. Tripodi A, Chantarangkul V, Mannucci PM. The International normalized ratio to prioritize patients for liver transplantation. Problems and possible solutions. J Thromb Haemost 2008;6:243-248
35. Favaloro EJ, Adcock D. Standardization of the INR: How good is your laboratory's INR and can it be improved? Semin Thromb Hemost 2008;34:593-603
36. Italian CISMEL Study Group, Ciavarella N, Eder G, Mannucci PM, Mariani G, et al. Multicenter comparison of nine coagulometers and manual tilt-tube methods for prothrombin time performance. Clin Lab Haematol 1983;5:177-184
37. Triplett DA. New methods in coagulation. Crit Rev Clin Lab Sci 1981;15:25-84
38. Tripodi A, Mannucci PM. Clinical evaluation of a fully automated chromogenic method for prothrombin time compared with a conventional coagulation method. Clin Chem 1984;30:1392-1395
39. Tripodi A, Poggio M, Scapellato L, Mannucci PM. Automated amidolytic method for activated partial thromboplastin time compared with a conventional coagulation method. Haemostasis 1989;19:205-212
40. Frantzen Handeland G, Abildgaard U, Aasen AO. Simplified assay for antithrombin III activity using chromogenic peptide substrate. Manual and automated method. Scand J Haematol 1983;31:427-436
41. Tang JC, Li S, McGray P, Vecchio A. Current status of activity assays for tissue plasminogen activator. Ann N Y Acad Sci 1984;434:536-540
42. Tripodi A, Mannucci PM. Factor VIII activity as measured by an amidolytic assay compared with a one-stage clotting assay. Am J Clin Pathol 1986;86:341-344
43. Franchi F, Tripodi A, Valsecchi C, Mannucci PM. Functional assay of protein C: comparison of two snake-venom assays with two thrombin assays. Thromb Haemost 1988;60:145-148
44. Macfarlane RG, Biggs R. A thrombin generation test. J Clin Pathol 1953;6:3-7
45. Hemker HC, Willems GM, Béguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986;56:9-17
46. Hemker HC, Wielders S, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993;70:617-624
47. Hemker HC, Giesen PL, Ramjee M, Wagenvoord R, Béguin S. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000;83:589-591
48. Hartert H. Blutgerninnungstudien mit der thromboelastographic. Einen neven Untersuchingsver Farhen Klinische Wocheschrift 1948;16:257-260
49. Caprini JA, Traverso CI, Arcelus JI. Perspectives on thromboelastography. Semin Thromb Hemost 1995;21(Suppl 4):91-93
50. Gillies BS. Thromboelastography and liver transplantation. Semin Thromb Hemost 1995;(21 Suppl 4):45-49
51. Mancuso A, Fung K, Cox D, et al. Assessment of blood coagulation in severe liver disease using thromboelastography: use of citrate storage versus native blood. Blood Coagul Fibrinolysis 2003;14:211-216